Overview
Acinetobacter baumannii is a Gram-negative bacterium known for causing severe nosocomial infections, particularly in intensive care units (ICUs), often exhibiting multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes 13.Diagnosis
Blood cultures are crucial for identifying A. baumannii infections, with high positivity rates in clinical settings 3.
Serological tests like the serum bactericidal test (SBT) may predict mortality in MDRAB infections, especially in patients without multiple organ failure or rapidly fatal disease 4.Management
Polymyxins are often the last line of defense for treating MDR and XDR A. baumannii infections due to their limited resistance profile 4.
The serum bactericidal test (SBT) can guide prognosis and potentially inform treatment decisions, particularly in regions with limited therapeutic options 4.Special Populations
Haematology Patients: XDR A. baumannii infections in haematology clinics have high mortality rates, especially in patients with relapsed or non-remitting malignancies 3.
Elderly and Comorbidities: Specific management strategies for elderly patients or those with comorbidities are not detailed in the provided abstracts, but these populations may face increased severity and mortality 34.Key Recommendations
Utilize blood cultures for definitive diagnosis of A. baumannii infections 3.
Consider serum bactericidal titers as a prognostic tool in regions with limited treatment options for MDRAB, particularly in patients without multiple organ failure 4 (Evidence: Moderate).
Implement rigorous infection control measures in ICUs and haematology units to mitigate transmission, given the asymptomatic carriage and high colonization rates 2 (Evidence: Moderate).
Prioritize polymyxin use for treating MDR and XDR A. baumannii infections due to their efficacy against resistant strains 4 (Evidence: Weak).References
1 Afshan G, Yaseen N, Ali SH, Khan AU. Immunoinformatics-Based development of a Multi-Epitope vaccine candidate targeting coinfection by Klebsiella pneumoniae and Acinetobacter baumannii. BMC infectious diseases 2025. link
2 Doan TN, Kong DC, Marshall C, Kirkpatrick CM, McBryde ES. Characterising the Transmission Dynamics of Acinetobacter baumannii in Intensive Care Units Using Hidden Markov Models. PloS one 2015. link
3 Metan G, Pala Ç, Kaynar L, Cevahir F, Alp E. A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannnii. Le infezioni in medicina 2014. link
4 Liao CH, Sheng WH, Chen YC, Hung CC, Wang JT, Chang SC. Predictive value of the serum bactericidal test for mortality in patients infected with multidrug-resistant Acinetobacter baumannii. The Journal of infection 2007. link